Curated News: Journal of Experimental Medicine

• share
• favorite_border

Researchers at Cornell have developed a way to analyze how individual immune cells react to the bacteria that cause tuberculosis. It could pave the way for new vaccine strategies and provide insights into fighting other infectious diseases.

• share
• favorite_border

Researchers at Weill Cornell Medicine and NewYork-Presbyterian in New York have discovered that injecting mice with pulmonary endothelial cells—the cells that line the walls of blood vessels in the lung—can reverse the symptoms of emphysema. The study, which will be published July 21 in the Journal of Experimental Medicine (JEM), may lead to new treatments for chronic obstructive pulmonary disease (COPD), an inflammatory lung disease associated with smoking that is thought to be the third leading cause of death worldwide.

• share
• favorite_border

Exposure to the rhinovirus, the most frequent cause of the common cold, can protect against infection by the virus which causes COVID-19, Yale researchers have found.

• share
• favorite_border

St. Jude immunologists are researching how effector and killer T cells can be controlled to destroy cancer cells that resist treatment.

• share
• favorite_border

Up to half of patients with head and neck squamous cell carcinoma will experience tumor recurrence or new tumors—tumors that often spread and are difficult to treat.

• share
• favorite_border

DALLAS – May 12, 2021 – Scientists with UT Southwestern’s Peter O’Donnell Jr. Brain Institute have identified the molecular mechanism that can cause weight gain for those using a common antipsychotic medication. The findings, published in the Journal of Experimental Medicine, suggest new ways to counteract the weight gain, including a drug recently approved to treat genetic obesity, according to the study, which involved collaborations with scientists at UT Dallas and the Korea Advanced Institute of Science and Technology.

• share
• favorite_border

Using a mouse model, researchers discover pivotal role of cholesterol in chronic pain often caused by chemotherapy, and propose novel therapy.

• share
• favorite_border

Using whole exome sequencing, CHOP researchers discovered the genetic mutation responsible for a condition that prevents patients from making B cells and antibodies to fight infections. The study describing the condition, which CHOP researchers named PU.1 Mutated agammaglobulinemia (PU.MA), was published today in the Journal of Experimental Medicine.

• share
• favorite_border

New basic science research shows what happens to the development of abdominal aortic aneurysms when you inhibit JMJD3 through both genetics and pharmacology.

• share
• favorite_border

A novel mechanism has been identified that might explain why a rare mutation is associated with familial Alzheimer’s disease in a new study by investigators at the University of Chicago.

• share
• favorite_border

Researchers at the University of California, San Francisco, have discovered that aggressive, triple-negative breast cancers (TNBCs) can evade treatment by reorganizing and softening the collagen matrix that surrounds the cancer cells. The study, which will be published April 2 in the Journal of Experimental Medicine (JEM), shows that the softer matrix activates a signaling pathway that promotes the cancer cells’ survival, and suggests that targeting this pathway could enhance the effectiveness of chemo- and radiotherapy in TNBC patients.

• share
• favorite_border

Researchers at the University of Alabama at Birmingham have identified a new molecular target that could potentially treat the deadly, aging-related lung disease idiopathic pulmonary fibrosis (IPF). The study, which will be published March 10 in the Journal of Experimental Medicine (JEM), suggests that targeting a protein called MDM4 could prevent respiratory failure by initiating a genetic program that removes scar tissue from the lungs.

• share
• favorite_border

Researchers at UC San Diego School of Medicine and elsewhere have identified a new drug that could prevent AD by modulating, rather than inhibiting, a key enzyme involved in forming amyloid plaques.

• share
• favorite_border

According to a new study led by Yale Cancer Center and Department of Neurology researchers, a simple blood draw may be the first step in helping to discover tumor reactive immune or T cells to treat advanced melanoma, a deadly form of skin cancer. The findings were published today in the Journal of Experimental Medicine.